title: Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study.
abstract: BACKGROUND
  Glucagon-like peptide-1 is an incretin hormone essential for normal human glucose homeostasis. Expression of the glucagon-like peptide-1 receptor in the myocardium has fuelled growing interest in the direct and indirect cardiovascular effects of native glucagon-like peptide-1, its degradation product glucagon-like peptide-1(9-36), and the synthetic glucagon-like peptide-1 receptor agonists. Preclinical studies have demonstrated cardioprotective actions of all three compounds in the setting of experimental myocardial infarction and left ventricular systolic dysfunction. This has led to Phase 2 trials of native glucagon-like peptide-1 and incretin-based therapies in humans with and without Type 2 diabetes mellitus. These studies have demonstrated the ability of glucagon-like peptide-1, independent of glycaemic control, to positively modulate the metabolic and haemodynamic parameters of individuals with coronary artery disease and left ventricular systolic dysfunction. We aim to add to this growing body of evidence by studying the effect of chronic glucagon-like peptide-1 receptor activation on exercise-induced ischaemia in patients with chronic stable angina managed conservatively or awaiting revascularisation. The hypothesis being liraglutide, a subcutaneously injectable glucagon-like peptide-1 receptor agonist, is able to improve exercise haemodynamics in patients with obstructive coronary artery disease when compared with saline placebo.
  
  
  METHODS
  The Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) trial is an investigator-initiated single-centre randomised double-blinded placebo-controlled crossover proof-of-principle physiological study. Primary endpoints are change in rate pressure product at 0.1 mV ST-segment depression and change in degree of ST-segment depression at peak exercise during sequential exercise tolerance testing performed over a 6-week study period in which 26 patients will be randomised to either liraglutide or saline with crossover to the opposing regimen at week 3.
  
  
  CONCLUSIONS
  The study will be conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki. The local Research Ethics Committee and Medicines and Healthcare Products Regulatory Agency have approved the study.
  
  
  BACKGROUND
  National Institute of Health Research Clinical Research Network (NIHR CRN) Portfolio ID 11112 and ClinicalTrials.gov Identifier NCT02315001.
authors.forename: Aung
authors.initials: A
authors.lastname: Myat
authors.forename: Satpal
authors.initials: S
authors.lastname: Arri
authors.forename: Deepak L
authors.initials: DL
authors.lastname: Bhatt
authors.forename: Bernard J
authors.initials: BJ
authors.lastname: Gersh
authors.forename: Simon R
authors.initials: SR
authors.lastname: Redwood
authors.forename: Michael S
authors.initials: MS
authors.lastname: Marber
mesh_terms: D060050:Angina, Stable / Q000175:diagnosis / Q000188:drug therapy; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005080:Exercise Test / Q000187:drug effects* / Q000379:methods; D000067757:Glucagon-Like Peptide-1 Receptor / Q000378:metabolism; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000069450:Liraglutide / Q000494:pharmacology / Q000627:therapeutic use*; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
references.citation: Heart. 2012 Mar;98(5):408-13
references.pmid: 21561896
references.citation: N Engl J Med. 2013 Oct 3;369(14):1327-35
references.pmid: 23992602
references.citation: J Pharmacol Exp Ther. 2005 Jan;312(1):303-8
references.pmid: 15356213
references.citation: Diabetes. 2005 Jan;54(1):146-51
references.pmid: 15616022
references.citation: Circ Cardiovasc Interv. 2011 Jun;4(3):266-72
references.pmid: 21586690
references.citation: Eur Heart J. 2007 Jul;28(13):1543-4
references.pmid: 17562670
references.citation: Heart. 2002 Dec;88(6):604-10
references.pmid: 12433889
references.citation: Endocrinology. 2010 Apr;151(4):1520-31
references.pmid: 20172966
references.citation: J Card Fail. 2006 Dec;12(9):694-9
references.pmid: 17174230
references.citation: J Clin Invest. 1967 Dec;46(12):1954-62
references.pmid: 6074000
references.citation: J Am Coll Cardiol. 2009 Feb 10;53(6):501-10
references.pmid: 19195607
references.citation: Diabetes. 2014 Apr;63(4):1224-33
references.pmid: 24296712
references.citation: Circ Res. 2014 May 23;114(11):1788-803
references.pmid: 24855202
references.citation: Am J Cardiol. 2007 Sep 1;100(5):824-9
references.pmid: 17719327
references.citation: Diabetes. 1995 Sep;44(9):1126-31
references.pmid: 7657039
references.citation: J Clin Invest. 1993 Jan;91(1):301-7
references.pmid: 8423228
references.citation: J Am Coll Cardiol. 2003 Apr 2;41(7):1174-82
references.pmid: 12679219
references.citation: Endocrinology. 2003 Jun;144(6):2242-52
references.pmid: 12746281
references.citation: Peptides. 2003 Apr;24(4):569-78
references.pmid: 12860201
references.citation: N Engl J Med. 2013 Oct 3;369(14):1317-26
references.pmid: 23992601
references.citation: Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2401-8
references.pmid: 16024574
references.citation: Lancet. 1987 Dec 5;2(8571):1300-4
references.pmid: 2890903
references.citation: Regul Pept. 1994 Apr 14;51(1):63-74
references.pmid: 8036284
references.citation: Circ Cardiovasc Imaging. 2014 Mar;7(2):274-81
references.pmid: 24503784
references.citation: J Pharmacol Exp Ther. 2006 Jun;317(3):1106-13
references.pmid: 16489128
references.citation: J Clin Endocrinol Metab. 1964 Oct;24:1076-82
references.pmid: 14228531
references.citation: Heart. 2014 Oct;100(19):1550-61
references.pmid: 24747994
references.citation: Lancet. 2002 Mar 9;359(9309):824-30
references.pmid: 11897280
references.citation: Lancet. 2006 Nov 11;368(9548):1696-705
references.pmid: 17098089
references.citation: Circ Cardiovasc Imaging. 2010 Mar;3(2):195-201
references.pmid: 20075143
references.citation: Eur Heart J. 2005 Mar;26(6):598-606
references.pmid: 15618027
references.citation: Circulation. 2013 Jan 1;127(1):74-85
references.pmid: 23186644
references.citation: Regul Pept. 2008 Feb 7;146(1-3):243-9
references.pmid: 17976835
references.citation: Physiol Rev. 2007 Oct;87(4):1409-39
references.pmid: 17928588
references.citation: Heart. 2014 Jan;100(2):106-14
references.pmid: 23781112
references.citation: Circulation. 2012 Nov 27;126(22):2565-74
references.pmid: 23124033
references.citation: J Clin Endocrinol Metab. 1973 Nov;37(5):826-8
references.pmid: 4749457
references.citation: Circulation. 2004 Mar 2;109(8):962-5
references.pmid: 14981009
references.citation: Endocrinology. 2013 Jan;154(1):4-8
references.pmid: 23267050
references.citation: Nat Med. 2013 May;19(5):567-75
references.pmid: 23542788
references.citation: Endocr Rev. 2012 Apr;33(2):187-215
references.pmid: 22323472
references.citation: J Clin Endocrinol Metab. 2002 Aug;87(8):3768-73
references.pmid: 12161508
references.citation: Diabetologia. 1986 Jan;29(1):46-52
references.pmid: 3514343
references.citation: J Clin Endocrinol Metab. 1993 Apr;76(4):912-7
references.pmid: 8473405
references.citation: Lancet. 2009 Nov 7;374(9701):1606-16
references.pmid: 19853906
references.citation: Diabetes. 1996 Nov;45(11):1524-30
references.pmid: 8866556
references.citation: Circulation. 2008 May 6;117(18):2340-50
references.pmid: 18427132
references.citation: Diabetologia. 2002 Aug;45(8):1111-9
references.pmid: 12189441
references.citation: Diabetes. 2009 Apr;58(4):975-83
references.pmid: 19151200
references.citation: Circ Heart Fail. 2008 Sep;1(3):153-60
references.pmid: 19727407
references.citation: Eur Heart J. 2012 Jun;33(12):1491-9
references.pmid: 21920963
references.citation: Am J Physiol Heart Circ Physiol. 2010 Mar;298(3):H1096-102
references.pmid: 20081109